115 related articles for article (PubMed ID: 17640696)
1. Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay.
Pontow S; Harmon B; Campbell N; Ratner L
Virology; 2007 Nov; 368(1):1-6. PubMed ID: 17640696
[TBL] [Abstract][Full Text] [Related]
2. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
3. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
4. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
5. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
6. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y
Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245
[TBL] [Abstract][Full Text] [Related]
7. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
[TBL] [Abstract][Full Text] [Related]
9. Is there a future for antiviral fusion inhibitors?
Berkhout B; Eggink D; Sanders RW
Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
11. Gold nanoparticles as an HIV entry inhibitor.
Vijayakumar S; Ganesan S
Curr HIV Res; 2012 Dec; 10(8):643-6. PubMed ID: 22954307
[TBL] [Abstract][Full Text] [Related]
12. An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity.
Borrego P; Calado R; Marcelino JM; Pereira P; Quintas A; Barroso H; Taveira N
AIDS; 2013 Apr; 27(7):1081-90. PubMed ID: 23324659
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of HIV-1 mediated cell-cell fusion by saponin fraction from Psidium guajava leaf].
Mao QC; Zhou YC; Li RM; Hu YP; Liu SW; Li XJ
Zhong Yao Cai; 2010 Nov; 33(11):1751-4. PubMed ID: 21434438
[TBL] [Abstract][Full Text] [Related]
16. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activities of extracts of Euphorbia hirta L. against HIV-1, HIV-2 and SIVmac251.
Gyuris A; Szlávik L; Minárovits J; Vasas A; Molnár J; Hohmann J
In Vivo; 2009; 23(3):429-32. PubMed ID: 19454510
[TBL] [Abstract][Full Text] [Related]
18. Are fusion inhibitors active against all HIV variants?
Poveda E; Rodes B; Toro C; Soriano V
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):347-8. PubMed ID: 15117459
[TBL] [Abstract][Full Text] [Related]
19. Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle.
Daelemans D; Dumont JM; Rosenwirth B; De Clercq E; Pannecouque C
Antiviral Res; 2010 Feb; 85(2):418-21. PubMed ID: 19857522
[TBL] [Abstract][Full Text] [Related]
20. Discovery of natural mouse serum derived HIV-1 entry inhibitor(s).
Wei M; Chen Y; Xi J; Ru S; Ji M; Zhang D; Fang Q; Tang B
Acta Virol; 2016; 60(4):404-409. PubMed ID: 27928921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
